Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Papillomavirus Infections 1Non-melanomatous Skin Cancer 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 6Radiotherapy, Intensity-Modulated 5Cisplatin 5Carboplatin 5Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4artesunic acid 3artemisinin 3Paclitaxel 3Human Papillomavirus Recombinant Vaccine nonavalent 3artenimol 2Vaccines, Synthetic 2Taxes 2Radiation 2Imiquimod 2GX-188 vaccine 2Docetaxel 2Albumin-Bound Paclitaxel 2utomilumab 1toripalimab 1polyphenon E 1infigratinib 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Viusid 1Vaccines 1VP-102 1Therapies, Investigational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Papillomavirus Infections × polyphenon E × Clear all
NCT00303823 2015-05-05

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
98 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡